4.0 Article

Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis

期刊

ARCHIVES OF NEUROLOGY
卷 65, 期 6, 页码 809-811

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/archneur.65.6.809

关键词

-

向作者/读者索取更多资源

Background: Vitamin D-dependent rickets type I (VDDR I) (OMIM 264700) is a rare hereditary condition caused by a mutation in CYP27B1. Vitamin D is emerging as an important risk factor for susceptibility to multiple sclerosis (MS), but there have been no studies on the possible association between hereditary rickets and this disease. Objective: To investigate the association between VDDR I and MS. Design: Case studies. Setting: Haukeland University Hospital, Bergen, Norway. Patients: Three patients in 2 families with a cooccurrence of VDDR I and MS. Results: All 3 patients had VDDR I verified by genetic testing and fulfilled the Poser criteria for MS. Two of the patients have undergone magnetic resonance imaging, which confirmed the diagnosis of long-lasting MS. Conclusions: Vitamin D -dependent rickets type I is a very uncommon genetic subtype of rickets. We have identified 3 patients with this disease who later developed MS. We propose that VDDR I and possibly other hereditary rickets mutations that influence vitamin D metabolism could be risk factors for this disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations

Marton Konig, Aslaug Rudjord Lorentzen, Hilde Marie Torgauten, The Trung Tran, Stine Schikora-Rustad, Eline Benno Vaage, Ase Mygland, Stig Wergeland, Jan Aarseth, Ingeborg Aase S. Aaberge, Oivind Torkildsen, Trygve Holmoy, Tone Berge, Kjell-Morten Myhr, Hanne Flinstad Harbo, Jan Terje Andersen, Ludvig Andre Munthe, Arne Soraas, Elisabeth Gulowsen Celius, John Torgils Vaage, Fridtjof Lund-Johansen, Gro Owren Nygaard

Summary: This study aimed to characterize humoral immunity after mRNA-COVID-19 vaccination in people with multiple sclerosis (pwMS). The study found that patients treated with fingolimod or rituximab had reduced humoral immunity. It is important to carefully time the vaccinations for patients treated with rituximab.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Association of adverse childhood experiences with the development of multiple sclerosis

Karine Eid, Oivind Torkildsen, Jan Aarseth, Mari Aalstad, Alok Bhan, Elisabeth G. Celius, Marianna Cortese, Anne Kjersti Daltveit, Trygve Holmoy, Kjell-Morten Myhr, Trond Riise, Stephan Schuler, Cecilie F. Torkildsen, Stig Wergeland, Nils Erik Gilhus, Marte-Helene Bjork

Summary: This study found that childhood sexual and emotional abuse were associated with an increased risk of developing multiple sclerosis (MS). The risk was higher for those exposed to multiple categories of abuse.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

Letter Clinical Neurology

Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis

Gro Owren Nygaard, Hilde Torgauten, Lars Skattebol, Einar August Hogestol, Piotr Sowa, Kjell-Morten Myhr, Oivind Torkildsen, Elisabeth Gulowsen Celius

Summary: Rebound disease activity can occur after switching from fingolimod to cladribine or rituximab in the treatment of multiple sclerosis (MS). This study found that the risk of rebound was lower when switching to rituximab compared to cladribine, indicating a better initial clinical outcome with rituximab.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Article Clinical Neurology

Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes

Anne Lise K. Hestvik, Jette Lautrup Frederiksen, Helle Hvilsted Nielsen, Oivind Torkildsen, Camilla Eek, Yumin Huang-Link, Sara Haghighi, Jon A. Tsai, Matthias Kant

Summary: This study found that teriflunomide treatment for multiple sclerosis resulted in stable quality of life, decreased relapse activity, and high treatment satisfaction.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Article Clinical Neurology

Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy

Karine Eid, Oivind Torkildsen, Jan Aarseth, Elisabeth G. Celius, Marianna Cortese, Trygve Holmoy, Akash Kapali, Kjell-Morten Myhr, Cecilie F. Torkildsen, Stig Wergeland, Nils Erik Gilhus, Marte-Helene Bjork

Summary: Women with multiple sclerosis (MS) are more likely to experience systematic emotional abuse, rape, and revictimization as adults compared to women without MS.

JOURNAL OF NEUROLOGY (2022)

Article Clinical Neurology

Safety of breast feeding during rituximab treatment in multiple sclerosis

Brit Ellen Rod, Oivind Torkildsen, Kjell-Morten Myhr, Lars Bo, Stig Wergeland

Summary: Our study found minimal transfer of rituximab into breast milk in nursing mothers, and the levels of rituximab in infant serum were difficult to detect. The B cell counts in infants were unaffected.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis

Ingrid Anne Lie, Kristin Wesnes, Silje S. Kvistad, Iman Brouwer, Stig Wergeland, Trygve Holmoy, Rune Midgard, Alla Bru, Astrid Edland, Randi Eikeland, Sonia Gosal, Hanne F. Harbo, Grethe Kleveland, Yvonne S. Sorenes, Nina Oksendal, Frederik Barkhof, Hugo Vrenken, Kjell-Morten Myhr, Lars Bo, Oivind Torkildsen

Summary: This study assessed the long-term effects of smoking on patients with RRMS. The results showed that smoking was associated with brain atrophy and disability progression, suggesting that patients should quit smoking shortly after diagnosis to prevent long-term disability progression.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)

Letter Clinical Neurology

Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis

Ingrid Anne Lie, Brit Ellen Rod, Silje Stokke Kvistad, Trygve Holmoy, Kjell-Morten Myhr, Oivind Torkildsen, Stig Wergeland

Summary: This study investigated the effect of IFN beta-1a treatment on serum EBV antibody levels in patients with relapsing-remitting MS and found no significant associations between treatment and EBV antibody levels.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Article Clinical Neurology

Cancer related mortality in multiple sclerosis. A population based cohort study

Nina Grytten, Kjell-Morten Myhr, Elisabeth G. Celius, Espen Benjaminsen, Rune Midgard, Anita Vatne, Jan H. Aarseth, Janne Mannseth, Oivind Torkildsen

Summary: This study aims to determine the differences in all-cause mortality and mortality following a cancer diagnosis between multiple sclerosis (MS) patients and matched population controls. The study found that the all-cause mortality among MS patients was five times higher than that of the controls, and the mortality following a cancer diagnosis was two times higher. In addition, MS patients had higher mortality rates following urinary system, colorectal, hematological, ovarian, and breast cancer diagnoses. High education was inversely associated with mortality among MS patients.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Article Clinical Neurology

Predictors of hospitalization due to infection in rituximab-treated MS patients

Jakob Rishovd Karlowicz, Mattias Klakegg, Jan Harald Aarseth, Lars Bo, Kjell-Morten Myhr, Hilde Marie Torgauten, Oivind Torkildsen, Stig Wergeland

Summary: This retrospective cohort study found that patients with multiple sclerosis (MS) treated with rituximab had a higher risk of hematological adverse events, including hypogammaglobulinemia, severe lymphopenia, neutropenia, and infections leading to hospitalization. The risk was higher in patients with longer treatment duration, lympho- or neutropenia, and primary progressive MS.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Meeting Abstract Clinical Neurology

Safety of a third SARS-CoV-2 mRNA vaccine dose in people with multiple sclerosis

T. H. Rasmussen, M. Konig, A. R. Lorentzen, S. Schikora-Rustad, T. Berge, T. Holmoy, O. Torkildsen, S. Wergeland, M. H. Overas, E. A. Hogestol, H. M. Torgauten, H. F. Harbo, E. G. Celius, L. A. Munthe, J. T. Vaage, F. L. Johansen, G. O. Nygaard

MULTIPLE SCLEROSIS JOURNAL (2022)

Meeting Abstract Clinical Neurology

Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS

T. Kalincik, S. Sharman, I. Roos, M. Freedman, H. Atkins, J. Burman, J. Massey, I. Sutton, B. Withers, R. Macdonell, A. Grigg, O. Torkildsen, L. Bo, A. Lehmann, D. Horakova, E. Havrdova, E. Krasulova, M. Trneny, T. Kozak, A. van der Walt, H. Butzkueven, P. McCombe, B. Van Wijmeersch, K. Buzzard, O. Skibina, J. Lechner-Scott, B. Willekens, M. Barnett, E. Cartechini, S. Ozakbas, R. Alroughani, G. Izquierdo, S. Eichau, C. Boz, J. Kuhle, F. Patti, M. Terzi, A. Prat, M. Girard, P. Duquette, P. Grammond, M. Onofrj, A. Lugaresi, S. Khoury, A. Soysal, M. Slee, J. Prevost, R. Turkoglu, B. Sharrack, J. Snowden

MULTIPLE SCLEROSIS JOURNAL (2022)

Meeting Abstract Clinical Neurology

Comparative effectiveness of autologous haematopoietic stem cell transplantation with immune reconstitution therapies in relapsing-remitting MS

T. Kalincik, S. Sharmin, I. Roos, M. S. Freedman, H. Atkins, J. Burman, J. Massey, I. Sutton, B. Withers, R. Macdonell, A. Grigg, O. Torkildsen, L. Bo, A. K. Lehmann, D. Horakova, E. K. Havrdova, E. Krasulova, M. Trneny, T. Kozak, A. van der Walt, H. Butzkueven, B. Van Wijmeersch, P. McCombe, K. Buzzard, O. Skibina, J. Lechner-Scott, B. Willekens, M. Barnett, E. Cartechini, G. Izquierdo, S. Eichau, F. Patti, S. Hodgkinson, J. Prevost, M. Onofrj, A. Lugaresi, R. Alroughani, E. Butler, A. Prat, M. Girard, P. Duquette, P. Grammond, F. Grand'Maison, G. Laureys, L. Van Hijfte, D. Maimone, B. Sharrack, J. Snowden

MULTIPLE SCLEROSIS JOURNAL (2022)

Meeting Abstract Clinical Neurology

Effectiveness of autologous haematopoietic stem cell transplantation in comparison with natalizumab in progressive MS

T. Kalincik, S. Sharmin, I. Roos, J. Massey, I. Sutton, B. Withers, M. Freedman, H. Atkins, D. Horakova, E. Kubala Havrdova, E. Krasulova, M. Trneny, T. Kozak, J. Burman, R. Macdonell, A. Grigg, O. Torkildsen, L. Bo, A. K. Lehmann, B. Sharrack, J. Snowden

MULTIPLE SCLEROSIS JOURNAL (2022)

暂无数据